Population pharmacokinetic modeling of furosemide in patients with hypertension and fluid overload conditions

Kodati, Devender; Yellu, Narsimha Reddy

doi:10.1016/j.pharep.2017.01.006

Cited by 7 publications

(4 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As this equation incorporates WT, it may conceal the effect of WT on drug CL. The strong correlation between WT and CL CR was shown as WT was repeatedly eliminated as a significant covariate when estimated CL CR was added to the model, 22,27,28,33,40 even in partial or nonrenally eliminated 20,44 drugs such as carvedilol. Indeed, less than 2% of the carvedilol dose is excreted in its unmetabolized form in the urine.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Influence of Weight and Body Size on the Pharmacokinetics of Heart Failure Pharmacotherapy: A Systematic Review

et al. 2023

View full text Add to dashboard Cite

Objective: To conduct a review of studies evaluating the influence of body size and weight (WT) on the pharmacokinetics (PK) of drugs recommended for heart failure (HF) treatment. Data Sources: A systematic search of the MEDLINE (1946 to April 2023) and EMBASE (1974 to April 2023) databases was conducted for articles that focused on the impact of WT or body size on the PK of drugs of interest used in HF patients. Study Selection and Data Extraction: Articles written in English or French related to the aim of our study were retained for analysis. Data Synthesis: Of 6493 articles, 20 were retained for analysis. Weight was associated with the clearance of digoxin, carvedilol, enalapril, and candesartan as well as the volume of distribution of eplerenone and bisoprolol. There was no documented direct impact of WT on the PK of furosemide, valsartan, and metoprolol, although these studies were limited or confounded by the small sample size, adjustment of PK factors by WT, or the use of the Cockroff-Gault equation for the evaluation of creatinine clearance, which includes WT. Relevance to Patient Care and Clinical Practice: This review highlights and summarizes the available data on the importance of WT on the PK of HF treatment. Conclusion: Considering the significant impact of WT on most HF drugs in this review, it may be important to further investigate it in the context of personalized therapy, particularly in patients presenting extreme WTs.

show abstract

Section: Discussionmentioning

confidence: 99%

“…The daily dose of furosemide was 40 mg. No significant effect of BSA or body WT on furosemide PK was observed. 40 However, it should be noted that CL CR , estimated with the Cockcroft-Gault equation, had a significant effect on furosemide CL/F.…”

Section: Loop Diureticsmentioning

confidence: 92%

Influence of Weight and Body Size on the Pharmacokinetics of Heart Failure Pharmacotherapy: A Systematic Review

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Three separate concentrations were examined over the course of three days for the inter-day variation investigations, and the % RSD was determined. Tables 6, 7, 8, and 9 13,14 display the results obtained for intraday and interday variations.…”

Section: Precisionmentioning

confidence: 99%

Development and Validation of HPTLC SIAM for Furosemide and Spironolactone

Vanjari¹

2023

Biosci., Biotech. Res. Asia

View full text Add to dashboard Cite

"Diuretics," like spirolactone and furosemide, help the kidneys eliminate excess water. It also reduces fluid-induced hypertension and maintains blood potassium levels. Both Furosemide (FRU) and Spironolactone (SPL) can be measured at the same time with the help of HPTLC chromatographic method that have been shown to be very selective and accurate. There are a number of causes of edema, and FRU can help with all of them, including hepatic cirrhosis, chronic congestive heart failure, and excessive blood pressure. Heart failure and ascites caused by hepatic diseases are commonly treated with spironolactone due to its properties as an aldosterone antagonist and potassium-sparing diuretic. HPTLC methods were developed in this research to determine FRU and SPL simultaneously without using the solvents generally needed in chromatographic procedures. The proposed HPTLC approach stood out as an analytical method for quality control laboratories due to its speed, low cost, and ability to concurrently determine the target chemicals with a small number of solvents. The selectivity, accuracy, and reproducibility of the procedures for the simultaneous determination of the pure and mixed drug forms studied were further confirmed by statistical analysis.

show abstract

“…Diuretics are considered the cornerstone for treatment of monogenic forms of HTN, such as the use of triamterene and amiloride in glucocorticoid-remediable aldosteronism; the use of spironolactone, eplerenone, and amiloride in syndrome of apparent mineralocorticoid excess, triamterene and amiloride in Liddle syndrome; and the use of thiazide diuretics in Gordon syndrome [ 70 ]. In addition, diuretics may also be the preferred first-line or adjunctive agent in hypertensive patients with fluid overload or edematous conditions [ 71 , 72 ].…”

Section: Diureticsmentioning

confidence: 99%

Antihypertensive agents: a long way to safe drug prescribing in children

Siddiqi

Shatat

2019

Pediatr Nephrol

View full text Add to dashboard Cite

Recently updated clinical guidelines have highlighted the gaps in our understanding and management of pediatric hypertension. With increased recognition and diagnosis of pediatric hypertension, the use of antihypertensive agents is also likely to increase. Drug selection to treat hypertension in the pediatric patient population remains challenging. This is primarily due to a lack of large, well-designed pediatric safety and efficacy trials, limited understanding of pharmacokinetics in children, and unknown risk of prolonged exposure to antihypertensive therapies. With newer legislation providing financial incentives for conducting clinical trials in children, along with publication of pediatric-focused guidelines, literature available for antihypertensive agents in pediatrics has increased over the last 20 years. The objective of this article is to review the literature for safety and efficacy of commonly prescribed antihypertensive agents in pediatrics. Thus far, the most data to support use in children was found for angiotensin-converting enzyme inhibitors (ACE-I), angiotensin receptor blockers (ARB), and calcium channel blockers (CCB). Several gaps were noted in the literature, particularly for beta blockers, vasodilators, and the long-term safety profile of antihypertensive agents in children. Further clinical trials are needed to guide safe and effective prescribing in the pediatric population.

show abstract

Population pharmacokinetic modeling of furosemide in patients with hypertension and fluid overload conditions

Abstract: The final population pharmacokinetic model was demonstrated to be appropriate and effective and it can be used to assess the pharmacokinetic parameters of furosemide in Indian patients with hypertension and fluid overload conditions.

Cited by 7 publications

References 22 publications

Influence of Weight and Body Size on the Pharmacokinetics of Heart Failure Pharmacotherapy: A Systematic Review

Influence of Weight and Body Size on the Pharmacokinetics of Heart Failure Pharmacotherapy: A Systematic Review

Development and Validation of HPTLC SIAM for Furosemide and Spironolactone

Antihypertensive agents: a long way to safe drug prescribing in children

Contact Info

Product

Resources

About